Do I Need a Fractional CRO for My Medical Device Company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Buying Committee Is a Small Hospital Ecosystem, Not a Single Decision Maker

In medical device sales, your buyer is never one person. The buying committee for a $50,000-$250,000 capital device (surgical robot accessory, diagnostic imaging tool, or single-use sterile instrument) includes the attending physician (clinical need, but no budget authority), the department head (credentialing and peer review), the hospital CFO or supply chain VP (capital expenditure approval, typically requires 3-5 year ROI projection with utilization rate assumptions), and the IT/informatics director (EHR integration, data security, HL7/FHIR compliance). For disposables or consumables (reagents, catheters, implants), the committee shrinks but adds a value analysis committee (VAC) that compares your product against two or three incumbents on cost-per-case, infection rates, and clinician training time. The fractional CRO must know that the VAC meets quarterly, so a January pitch means a June decision at earliest, and that the physician champion you recruited in March may transfer hospitals in April, resetting your entire deal.

Deal size and shape vary wildly by device class. A capital device sale is a single transaction of $80,000-$200,000, but includes a 30-day trial period, installation, training, and a 12-month service contract. A consumable deal is a multi-year GPO contract with committed volume tiers - $500,000-$2 million annually, but paid per unit with 60-90 day net terms. The fractional CRO must decide which shape fits your cash flow: capital deals give lump-sum revenue but require demo inventory ($10,000-$30,000 per unit) and a field service engineer; consumable deals produce recurring revenue but demand a 6-month inventory buffer and a sales team that can call on 50-100 hospitals. Budget approval for capital requires a capital expenditure request (CER) signed by the CFO, which needs a business case showing payback within 18 months - your fractional CRO must build a template CER for each target hospital, including their specific case volume, reimbursement rates, and competitor pricing they already pay.

Deals stall at two specific points: clinical evidence validation and integration scope. The physician says "I need to see three peer-reviewed studies in my specialty" - the fractional CRO must have a pre-approved list of 5-7 studies and a process to get a Key Opinion Leader (KOL) from a reference site on a 15-minute call. The IT director says "your device must integrate with Epic and Cerner" - the fractional CRO must know whether you have an HL7 interface or need a middleware vendor, and whether that adds $20,000-$50,000 to the deal cost that the CFO will reject. A fractional CRO who has sold into hospital systems before knows these stalling points are not objections but missing artifacts, and can pre-build the artifact pack for each deal stage.

The Sales Cycle Forces a High-Touch, Evidence-Based Motion That Kills Generalists

The sales motion for medical devices is not transactional and not SaaS-like. It is a hybrid of enterprise capital equipment selling and clinical education. Your fractional CRO must design a motion where the first call is not a demo but a clinical needs assessment: the rep (or the CRO themselves) sits with the OR nurse manager for 45 minutes, mapping their current workflow, pain points with existing devices, and the specific clinical metric they care about (reduction in OR time, lower infection rate, fewer device malfunctions). This call generates a "clinical brief" - a 3-page document that the physician champion uses to justify the trial to the VAC. The second call is a technical validation with the biomedical engineering team, who will inspect your device for FDA 510(k) clearance, sterilization compatibility, and battery safety. The third call is the financial justification with the supply chain director, where you present total cost of ownership versus the incumbent, including disposables, training, service, and downtime costs. This motion means your sales cycle is 6-9 months for the first 10 customers, compressing to 4-6 months once you have reference sites and published outcomes.

Ramp time for a fractional CRO in medical devices is 60-90 days, not the 30-day ramp common in SaaS. They must learn your specific regulatory status (FDA clearance date, ISO 13485 certification, any adverse event history), your clinical evidence portfolio (which studies exist, which are in progress, which KOLs are under contract), and your manufacturing capacity (lead times, minimum order quantities, sterilization turnaround). They cannot fake this knowledge - a hospital's VAC will ask "what is your device's classification under 21 CFR 880?" and the fractional CRO must answer without checking notes. Forecast behavior is uniquely unreliable in medical devices because a deal that is "verbal commitment" from a physician has a 30% chance of closing if the CFO has not yet signed the CER. A deal that has "trial completed" with positive feedback has a 60% chance, but only if the hospital has a budget cycle that aligns with your close date. The fractional CRO must build a forecast that weights deals by hospital budget cycle month, not by rep confidence, and must flag any deal where the CER has not been submitted to finance as "high risk" regardless of physician enthusiasm.

Pipeline shape is a funnel with a very wide top and a narrow, slow middle. For every 100 hospitals contacted, 20 will agree to a clinical needs assessment, 5 will agree to a trial, 2 will complete the trial, and 1 will purchase. The fractional CRO must ensure that the top of funnel is constantly fed with 300-500 hospitals in your target segment (e.g., community hospitals with 100-300 beds, academic medical centers with dedicated research budgets, or ambulatory surgery centers with high volume). The leak is not at the top but at the trial-to-purchase conversion: hospitals start a trial, the physician champion gets busy, the device sits unused for 60 days, and the trial ends with "inconclusive results." The fractional CRO must implement a trial management protocol: weekly check-ins with the champion, a structured data collection form for the first 10 cases, and a pre-scheduled debrief with the VAC on day 45 of the trial, not day 90.

What a Fractional CRO Looks Like in a Medical Device Company

The fractional CRO for a medical device company is not a SaaS generalist who "learned medical devices once." They are a former VP of Sales at a company like Intuitive Surgical, Stryker, Medtronic, or a smaller firm like Auris Health or Verb Surgical. They have personally sold capital equipment to hospital systems, managed a team of clinical specialists, and navigated GPO contracts with Vizient or Premier. They charge $15,000-$25,000 per month for 20-30 hours per week, plus a performance bonus tied to first 10 hospital contracts or $1 million in revenue, whichever comes first. They are not a coach who advises your existing sales team - they are the sales team. In a pre-revenue company with no salespeople, the fractional CRO is the sole revenue generator for the first 6-9 months, making their own calls, running their own trials, and closing their own deals. They own the entire revenue function: sales process design, CRM setup (HubSpot or Salesforce with medical device custom objects for trials, CERs, and regulatory docs), pricing and packaging (capital vs. consumable vs. lease), channel strategy (direct vs. distributors vs. GPO), and customer success (installation, training, service contracts).

In the first 90 days, the fractional CRO must complete five specific deliverables. First, a revenue model: map the total addressable hospitals in your target segment, estimate the number of trials you can run per quarter given your demo inventory and field service capacity, and produce a 12-month revenue forecast with monthly milestones. Second, a sales playbook: document the clinical needs assessment script, the technical validation checklist, the financial justification template, and the trial management protocol. Third, a reference site strategy: identify the first 3 target hospitals that are most likely to buy and become reference sites, and build a KOL agreement with each (discounted pricing, co-authored study, speaking slot at a conference). Fourth, a pricing and contracting framework: decide whether you sell direct or through a distributor (distributors take 20-30% margin but give you access to 50+ hospitals overnight), and whether you offer a lease option (capital equipment lease with $0 down, 36-month term, 8-10% interest). Fifth, a regulatory and compliance checklist: ensure your sales collateral is FDA-compliant (no off-label claims, no unsubstantiated efficacy statements), your contracts include indemnification and liability clauses, and your data privacy practices meet HIPAA requirements for any patient data collected during trials.

The operating cadence is weekly, not monthly. Every Monday, the fractional CRO sends a 1-page revenue report to the CEO and board: number of active trials, number of CERs submitted, number of contracts in legal review, and the 3 biggest risks to this month's close. Every Wednesday, they run a 30-minute pipeline review with any clinical specialists or field service engineers, reviewing each trial's progress against the protocol. Every Friday, they do a "deal doctor" session: for the 2-3 deals closest to close, they personally call the hospital CFO or supply chain director to unblock the CER. They attend every board meeting to present the revenue forecast and the top 5 deals, and they meet monthly with the CEO to discuss whether the company is ready to hire a full-time CRO.

The fractional CRO owns the revenue function but advises on product-market fit. They will tell you, based on hospital feedback, whether your device needs a different sterilization method, a smaller form factor, or a lower price point to compete. They will advise on clinical study design - which endpoints matter to hospital VACs (cost reduction, infection rate, OR time) and which KOLs to recruit for a multi-center study. They will advise on regulatory strategy - whether to pursue a 510(k) clearance for a modified version of your device that addresses a specific hospital need. But they do not own product development, regulatory affairs, or manufacturing - those are the CEO's domain. The line between own and advise is clear: if it touches a customer conversation, the fractional CRO owns it; if it touches a product decision, they advise.

The signal to convert to a full-time CRO is when you have 10-15 paying hospital customers, $2-3 million in annual recurring revenue from consumables or $1 million in capital sales, and a sales team of 3-5 people (clinical specialists, field service engineers, inside sales). At that point, the fractional CRO's 20-30 hours per week is insufficient to manage a growing team, build a channel partner program, and handle the increasing complexity of GPO contracts and multi-year agreements. The conversion should happen over 3-4 months: the fractional CRO transitions to full-time at $200,000-$250,000 base salary plus 0.5-1% equity and a 50% bonus tied to revenue targets. If revenue is growing faster than 20% quarter over quarter, convert earlier - the fractional CRO will be stretched thin and may miss opportunities to hire and train a team. If revenue is flat or growing slower than 10% quarter over quarter, do not convert - the problem is not the CRO's hours but the product-market fit or the sales motion, and a full-time CRO will not fix that.

The Regulatory and Compliance Trap That Kills Deals

Medical device sales have a regulatory dimension that SaaS companies never face. Your fractional CRO must ensure that every sales call, every trial, and every contract complies with the FDA's regulations on promotional claims, off-label use, and adverse event reporting. If a sales rep tells a surgeon "this device reduces infection rates by 50%" without a clinical study that specifically proves that claim, you have made an off-label claim that can trigger an FDA warning letter, a DOJ investigation, and a recall. The fractional CRO must write a "claims matrix" that lists every claim your sales team can make, the specific study or data that supports it, and the exact wording allowed. They must train every rep (or themselves, if they are the only rep) on the difference between "our device has shown a 30% reduction in OR time in a 100-patient study at Mayo Clinic" (allowed) and "our device cuts OR time in half" (not allowed). They must also ensure that every trial agreement includes a clause that the hospital will report any adverse events to the manufacturer within 24 hours, and that the manufacturer will report to the FDA within 30 days.

The compliance trap also extends to hospital procurement. Most hospitals require your company to have a supplier diversity certification (minority-owned, woman-owned, or veteran-owned) to qualify for certain contracts, and your fractional CRO must know whether you need one or can partner with a distributor who has one. They must also know that hospitals in the same health system (e.g., HCA, Kaiser, Ascension) share a single GPO contract, so selling to one hospital in the system may automatically qualify you for all hospitals in that system - but only if you have the right GPO pricing tier. The fractional CRO must negotiate your GPO contract before you start selling, not after, because the GPO will demand a 2-5% administrative fee and a 10-20% discount off your list price, and if you sign a contract with one hospital outside the GPO, you may lose the ability to negotiate with the GPO at all.

Why a Fractional CRO Beats a Full-Time Hire for Pre-Revenue Medical Device Companies

A full-time CRO at a pre-revenue medical device company is a luxury you cannot afford. The fully-loaded cost is $350,000-$450,000 (salary, bonus, equity, benefits, travel, demo equipment, and a sales development representative they will demand to hire). That is 35-45% of a typical Series A raise of $1-2 million, and it buys you one person who will spend their first 6 months learning the industry, building relationships, and making mistakes that cost you hospitals. A fractional CRO costs $180,000-$300,000 annually (at $15,000-$25,000 per month) but brings 10-15 years of medical device sales experience, an existing network of hospital contacts, and a playbook that took them years to develop. They have already made the mistakes - they know that the hospital CFO will ask for a 3-year ROI projection, that the IT director will demand an HL7 interface, and that the physician champion will leave for another hospital mid-trial. They can start generating pipeline in week 1, not month 6.

The risk of a full-time hire is not just cost but mis-hire. If you hire a full-time CRO who has only sold SaaS or software, they will fail in medical devices because they do not understand the clinical evidence requirement, the regulatory constraints, or the hospital budget cycle. If you hire a full-time CRO from a large medical device company (Medtronic, Stryker), they may struggle in a startup because they are used to a team of 50 reps, a marketing department, and a legal team that handles contracts. A fractional CRO from a smaller medical device company (Auris, Verb, or a startup that sold to a larger company) has the right balance: they know how to sell with limited resources, they know how to build a sales process from scratch, and they know how to work with a CEO who is also the head of product and the head of regulatory. They are not a luxury - they are the most cost-effective way to validate that your device can actually be sold before you commit to a full-time hire.

FAQ

How do I find a fractional CRO who actually knows medical devices, not just "healthcare SaaS"? Look for someone who has personally sold capital equipment to a hospital system, not just managed a team. Ask for their specific deal experience: "Tell me about the last capital equipment deal you closed - what was the device, the hospital, the budget cycle, and the clinical evidence you used." Require a reference from a hospital supply chain director they have worked with. Avoid anyone who says "I sold to hospitals" but cannot name the specific FDA classification of the device they sold or the GPO contract they negotiated.

What happens if my fractional CRO only closes 2 deals in 6 months - do I fire them or give them more time? Evaluate the deals they did not close. If they had 10 active trials, 5 CERs submitted, and 2 contracts in legal, but the hospitals delayed due to budget freezes or physician turnover, that is normal - give them 3 more months. If they had only 3 trials, no CERs submitted, and no contracts in legal, that is a process failure - fire them and find someone who can build a pipeline faster. The benchmark is 1 closed deal per 3 months for the first 12 months, scaling to 1 per month by month 18.

Should my fractional CRO also handle regulatory and clinical affairs, or is that separate? Separate. The fractional CRO advises on clinical study design (which endpoints matter to hospitals) and regulatory strategy (whether to pursue a 510(k) for a modified device), but they do not write the study protocol, manage the IRB submission, or handle the FDA submission. Those functions require a dedicated regulatory affairs consultant ($10,000-$20,000 per month) or a full-time hire if you are raising a Series B. The fractional CRO's job is to sell what you have, not to get it approved.

When do I stop using a fractional CRO and hire a full-time VP of Sales instead? When you have 10-15 customers, $2-3 million in ARR, and a sales team of 3-5 people. At that point, the fractional CRO's 20-30 hours per week is not enough to manage a team, build a channel program, and negotiate GPO contracts. Transition over 3-4 months: the fractional CRO becomes a full-time employee or you hire a new full-time VP of Sales and keep the fractional CRO as a board advisor for 6 months. Do not convert if revenue is flat or growing slowly - the problem is not the CRO's hours but the product or the market.

Sources